Clinical Study
Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension
Table 4
Live functions at baseline.
| | TIPS () | OCT-LAR () | |
| AST (U/L) | 94.6 ± 49.3 | 97.2 ± 37.3 | 0.89 | ALT (U/L) | 101.3 ± 57.2 | 100.8 ± 35.3 | 0.98 | TB (μmol/L) | 64.7 ± 16.9 | 51.9 ± 16.3 | 0.07 | Prothrombin time (s) | 17.6 ± 1.3 | 18.1 ± 1.8 | 0.51 |
|
|